These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 11753552)

  • 1. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation.
    Baron F; Siquet J; Schaaf-Lafontaine N; Baudoux E; Hermanne JP; Fillet G; Beguin Y
    Haematologica; 2002 Jan; 87(1):78-88. PubMed ID: 11801468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
    Roberts MM; Dyson P; Rawling C; Thorp D; Rawling T; White D; Horvath N; Bardy P; Hui CH; Dart GW; To LB; Hughes TP
    Cytotherapy; 2003; 5(6):534-41. PubMed ID: 14660049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
    Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
    Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic transplantation of selected CD34+ cells from peripheral blood: experience of 62 cases using immunoadsorption or immunomagnetic technique. Spanish Group of Allo-PBT.
    Urbano-Ispizua A; Solano C; Brunet S; de la Rubia J; Odriozola J; Zuazu J; Figuera A; Caballero D; Martínez C; García J; Sanz G; Torrabadella M; Alegre A; Pérez-Oteiza J; Jurado M; Oyonarte S; Sierra J; García-Conde J; Rozman C
    Bone Marrow Transplant; 1998 Sep; 22(6):519-25. PubMed ID: 9758337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
    Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia.
    Kobbe G; Fenk R; Neumann F; Bernhardt A; Steidl U; Kondakci M; Graef T; Aivado M; Vaupel M; Huenerlituerkoglu AN; Kronenwett R; Pape H; Hildebrand B; Germing U; Haas R
    Cytotherapy; 2004; 6(6):533-42. PubMed ID: 15764020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation.
    Passweg JR; Meyer-Monard S; Gregor M; Favre G; Heim D; Ebnoether M; Tichelli A; Gratwohl A
    Bone Marrow Transplant; 2002 Sep; 30(5):267-71. PubMed ID: 12209347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study.
    Lewalle P; Triffet A; Delforge A; Crombez P; Selleslag D; De Muynck H; Bron D; Martiat P
    Bone Marrow Transplant; 2003 Jan; 31(1):39-44. PubMed ID: 12621505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome.
    Montero A; Savani BN; Shenoy A; Read EJ; Carter CS; Leitman SF; Mielke S; Rezvani K; Childs R; Barrett AJ
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1318-25. PubMed ID: 17162214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation.
    Siegert W; Beyer J; Kingreen D; Blasczyk R; Baurmann H; Schwella N; Schleicher J; Kirsch A; Huhn D
    Bone Marrow Transplant; 1998 Sep; 22(6):579-83. PubMed ID: 9758347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Allogeneic peripheral blood stem cell transplantation for high-risk leukemia].
    Huang X; Wang F; Guo N
    Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1348-51. PubMed ID: 11930625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.